我们创新的研发管线
科望医药基于消除肿瘤微环境中的免疫抑制因子，以及重新激活衰竭的T细胞这两大研发策略，建立起下一代肿瘤免疫疗法的创新产品管线，其中6款候选药物已进入临床研究阶段。
-
AssetTargetIndicationsDiscoveryPreclinicalPh1Ph2Ph3Partner
-
ES104VEGF/DLL4
- BTC, CRC, OC
-
ES102OX40
- NSCLC, HNSCC
-
ES014CD39/TGF-β
- Solid Tumors
-
ES009LILRB2
- Solid Tumors
-
ES002CD39
- Solid Tumors
-
ES004SIRPα
- Solid Tumors
-
ES019 (BiME®)SIRPα/PD-L1
- SoIid Tumors
-
Other BiME® ProgramsSIRPα/TAA
- Solid Tumors
-
View MoreES104TargetVEGF/DLL4
- Discovery Preclinical Ph1 Ph2 Ph3
-
+chemo
-
View MoreES102TargetOX40
- Discovery Preclinical Ph1 Ph2 Ph3
-
+PD-1
-
View MoreES014TargetCD39/TGF-β
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/+chemo/+IOs
-
View MoreES009TargetLILRB2
- Discovery Preclinical Ph1 Ph2 Ph3
-
+PD-1
-
View MoreES002TargetCD39
- Discovery Preclinical Ph1 Ph2 Ph3
-
Combo
-
View MoreES004TargetSIRPα
- Discovery Preclinical Ph1 Ph2 Ph3
-
Combo
-
View MoreES019 (BiME®)TargetSIRPα/PD-L1
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/Combo
-
View MoreOther BiME® ProgramsTargetSIRPα/TAA
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/Combo
